MannKind Q2 2026 Earnings: Revenue Rises 43% as Costs Drive a Net Loss

MannKind Corporation (Nasdaq: MNKD) reported Q2 2026 revenue of $109.4 million, up 43% from $76.5 million a year earlier, while GAAP diluted EPS was negative $0.06 versus $0.00. The company recorded a $19.0 million net loss as higher launch spending, acquisition-related costs and financing expenses offset the revenue increase. The quarter also included the pediatric Afrezza approval, followed shortly after quarter-end by FDA approval of the Furoscix ReadyFlow autoinjector.

Core earnings data

Revenue growth came from the addition of Furoscix following the October 2025 acquisition of scPharma, a 53% increase in collaboration and services revenue, and higher royalties tied to United Therapeutics’ Tyvaso DPI sales. Afrezza and V-Go sales declined from the prior-year period.

Expenses rose faster than revenue. SG&A increased as MannKind promoted Furoscix and expanded its field operations for the pediatric Afrezza and ReadyFlow launches, while R&D spending increased for ReadyFlow and MNKD-201 development.

Non-GAAP results exclude items including stock compensation, acquired-intangible amortization, changes in contingent consideration and certain royalty-related expenses.

Business and product performance

Commercial product sales nearly doubled because Furoscix was not part of MannKind’s portfolio in Q2 2025. Collaboration and services revenue provided another major contribution, primarily reflecting increased product supplied to United Therapeutics and ralinepag DPI development revenue.

Revenue from marketed products increased 27% sequentially from Q1 2026. For Furoscix, doses purchased by integrated delivery networks rose 36% sequentially, while units dispensed through nephrology reached a record and increased 67%.

Afrezza received FDA approval on May 29 for children and adolescents aged six and older with diabetes. MannKind reported that one-third of the top 100 pediatric insulin prescribers had prescribed the product during its early launch. Furoscix ReadyFlow received FDA approval on July 23 for treating edema in adults with heart failure or chronic kidney disease, with commercial availability expected in late August.

In the pipeline, the Phase 1b INFLO-1 study of inhaled nintedanib, or MNKD-201, demonstrated safety and tolerability in patients with idiopathic pulmonary fibrosis. Site activation and enrollment were underway for the global Phase 2 INFLO-2 study. MannKind also remained on track to file an IND for ralinepag DPI by year-end and received $5 million from United Therapeutics to support its development.

Revenue growth did not translate into profit as operating and financing costs rose

Quarterly revenue increased by $32.8 million, but total expenses rose by approximately $38.5 million. Commercial cost of goods sold increased to $14.4 million from $4.6 million, mainly because Furoscix was added to the portfolio and carries a lower gross margin percentage than Afrezza. The company did not disclose an exact consolidated gross margin percentage.

SG&A accounted for the largest expense increase, rising by $26.7 million as MannKind supported Furoscix and prepared for two product launches. R&D increased by $4.3 million due to ReadyFlow development, higher personnel costs following the scPharma acquisition and spending on MNKD-201. These factors shifted the operating margin from approximately 6.9% in Q2 2025 to negative 0.3% in Q2 2026.

The larger GAAP net loss also reflected total other expense of $18.8 million, compared with $4.4 million a year earlier. Interest expense increased to $11.9 million from $0.3 million, and the quarter included $5.0 million of other expense related to a change in the fair value of contingent consideration.

Balance sheet and capital position

MannKind ended June with $52.9 million of cash and cash equivalents and $58.2 million of short-term investments, for a combined total of approximately $111.1 million. That was about $65.2 million below total cash and investments at the end of 2025. Inventory increased to $44.4 million from $35.3 million, while the term loan stood at $319.1 million.

After quarter-end, MannKind closed a $50 million private placement on July 24. The proceeds were designated to fund the $45 million contingent value rights payment triggered by FDA approval of Furoscix ReadyFlow.

Management perspective

CEO Michael Castagna characterized the pediatric Afrezza launch, ReadyFlow approval and positive MNKD-201 Phase 1b results as the three primary catalysts targeted for 2026. Management expects the two approvals to expand near-term commercial opportunities across diabetes, heart failure and chronic kidney disease, while the MNKD-201 data supported continued advancement into Phase 2.

Recent insider transactions

The supplied insider data identifies one open-market purchase by the CEO and more recent sales by a director and the general counsel. These transactions are presented without drawing conclusions about insiders’ views of the company’s prospects.

Risks investors should monitor

• Launch execution: Revenue benefits from pediatric Afrezza and ReadyFlow depend on adoption after their recent approvals. Early pediatric prescribing and Furoscix sequential growth are encouraging indicators, but they cover only an initial launch period.
• Margin and expense pressure: Furoscix has a lower gross margin percentage than Afrezza, while the commercial organization needed to support new launches contributed to an 84% increase in SG&A.
• Legacy product declines: Afrezza revenue fell 7% and V-Go revenue declined 33% year over year, leaving acquisition-related Furoscix revenue and collaboration income as major drivers of consolidated growth.
• Financing costs and capital requirements: Interest expense rose substantially, the term loan totaled $319.1 million and a $45 million contingent payment was triggered after quarter-end.
• Pipeline execution: MNKD-201 must progress through Phase 2, while ralinepag DPI still requires an IND filing before further clinical advancement.

Summary

MannKind’s Q2 revenue expanded sharply following the addition of Furoscix and higher collaboration income, but launch spending, R&D investment and financing costs pushed the company from a modest profit to a net loss. The next operating indicators are the adoption of pediatric Afrezza and ReadyFlow, Furoscix’s margin contribution, expense discipline and progress in the MNKD-201 and ralinepag DPI programs.